Bangkok Genomics Innovation Public Company (BKGI) Fair Value & Analysis
Healthcare · TH · Market cap 1.2B THB
Fair value as of: Jul 14, 2026
From 17 valuation models · updated 27 days ago
Share price −0.9% over the past month.
Below-average quality, and screening another 28% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1.89 THB). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 14, 2026.
How to read this chart
29‑month range 1.10 THB – 5.11 THB · fair‑value band 1.13 THB – 1.89 THB · the 2.10 THB price screens above the 1.51 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 14, 2026.
Analysis
Bangkok Genomics Innovation Public Company (BKGI) currently trades at 2.10 THB, while our model-based Fair Value estimate is 1.51 THB, implying the stock looks roughly 28.1% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Bangkok Genomics Innovation Public Company generated revenue of 453M THB at a net margin of 15.1%. Revenue grew 93.8% year over year. It earns a return on equity of 12.1%. The balance sheet holds a net cash position of 184M THB. Fundamentals as of Jul 14, 2026
Our scenario range runs from 1.13 THB (bear case) to 1.89 THB (bull case); at 2.10 THB, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 96% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -28%, BKGI screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (1.99 THB) versus Dividend Discount (0.6000 THB). Highest evidence: Residual Income (76).
Notify me when BKGI reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus …
Full company description
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; newborn screening; and health check-ups for various needs. Further, it supports research services in both medical and other fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers; NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions; real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits; and cell-free DNA storage tubes. The company serves government sectors such as medical schools and health centers, as well as private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bangkok Genomics Innovation Public Company reported revenue of 380M THB in FY2025 versus 379M THB in FY2021, a compound +0.0%/yr. Reported net income was 45.3M THB in FY2025, compounding −19.1%/yr from FY2021.
BKGI screens 28% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Bangkok Genomics Innovation Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bangkok Genomics Innovation Public Company (BKGI) overvalued or undervalued?
What is the fair value of BKGI?
What is the quality score of BKGI?
What is the revenue of Bangkok Genomics Innovation Public Company (BKGI)?
What is the net profit margin of BKGI?
Does Bangkok Genomics Innovation Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bangkok Genomics Innovation Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.